![](http://www.alamy.com/thumbs/6/80393F7D-61D4-4433-846D-8947B9B720F8/PKHKHC.jpg)
Ranibizumab monoclonal antibody fragment (Fab) drug. Targets Vascular endothelial growth factor A (VEGFA) and is indicated for the treatment of age-re
Ranibizumab monoclonal antibody fragment (Fab) drug. Targets Vascular endothelial growth factor A (VEGFA) and is indicated for the treatment of age-related macular degeneration (AMD). Closely related to bevacizumab. Generic name and stylized antibody representation.
Size: 6718px × 2446px
Photo credit: © molekuul.be / Alamy / Afripics
License: Royalty Free
Model Released: No
Keywords: age-related, amd, angiogenesis, anti-angiogenic, anti-vegf, antibody, bevacizumab, biological, biosimilar, biotech, biotechnology, degeneration, disease, drug, fab, humour, immunoglobulin, immunology, infusion, injection, inn, intravitreal, intravitreally, mab, macular, monoclonal, nomenclature, peptide, protein, ranibizumab, vitreous, wet